TOTAL CURRENT ASSETS TOTAL ASSETS Class of Stock [Axis] TOTAL CURRENT LIABILITIES TOTAL LIABILITIES TOTAL ADITXT, INC. STOCKHOLDERS’ EQUITY (DEFICIT) Stockholders’ equity TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) Balance Balance TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS’ EQUITY (DEFICIT) Gross profit Total operating expenses NET LOSS FROM OPERATIONS Total other expense Net loss before income taxes NET LOSS Net Loss Net loss NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES TOTAL COMPREHENSIVE LOSS Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Cash flow from operating activities Net cash used in investing activities Net cash provided by financing activities NET DECREASE IN CASH CASH AT BEGINNING OF PERIOD CASH AT END OF PERIOD Cash Organization and Nature of Business [Abstract] Going Concern Analysis [Abstract] Summary of Significant Accounting Policies [Abstract] Financial Instrument [Axis] Fair Value Hierarchy and NAV [Axis] Asset Class [Axis] Class of Warrant or Right [Axis] Schedule of Changes In Equity Investments [Abstract] As of December 31, 2025 As of March 31, 2026 Investment in Evofem Investments Schedule of Accounts Payable and Accrued Expenses [Abstract] Total accounts payable and accrued expenses Accounts payable and accrued expenses Measurement Input Type [Axis] Antidilutive Securities [Axis] Fixed Assets [Abstract] Long-Lived Asset, Class [Axis] Schedule of Fixed Asset Activity [Abstract] As of December 31, 2025 As of March 31, 2026 Cost Basis Intangible Assets [Abstract] Intangible Asset, Finite-Lived, Class [Axis] Schedule of Intangible Asset Activity [Abstract] As of December 31, 2025 As of March 31, 2026 Related Party Transactions [Abstract] Notes Receivable [Abstract] Valuation Approach and Technique [Axis] Statistical Measurement [Axis] Schedule of Changes in the Evofem Notes [Abstract] As of December 31, 2025 As of March 31, 2026 Convertible notes receivable, at fair value Fair value of Evofem notes Notes Payable [Abstract] Leases [Abstract] Total lease costs Total right of use asset Right of use asset Total lease liability Schedule of Maturities of Leases [Abstract] Total lease payments Commitments & Contingencies [Abstract] Total purchase price consideration Business Combination [Axis] Stockholders’ Equity [Abstract] Number, Outstanding beginning balance Number, Outstanding ending balance Weighted Average Exercise Price, Outstanding beginning balance Weighted Average Exercise Price, Outstanding ending balance Plan Name [Axis] Income Taxes [Abstract] Segment Reporting [Abstract] Subsequent Events [Abstract] ASSETS Assets CURRENT ASSETS: Accounts receivable, net Inventory Prepaid expenses Fixed assets, net Net Fixed assets Intangible assets, net Deposits Goodwill LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) CURRENT LIABILITIES: Mandatorily Redeemable, Preferred Stock Mandatorily Redeemable, Preferred Stock Shares (in Shares) Notes payable, net of discount Deferred rent Operating lease liability, current Operating lease liabilities – short term Less current portion Operating lease liability, long term Operating lease liabilities – long term Total maturities, due beyond one year Derivative liabilities Total derivative liability COMMITMENTS AND CONTINGENCIES MEZZANINE EQUITY TOTAL MEZZANINE EQUITY Mezzanine equity, par value (in Dollars per share) Mezzanine equity, share authorized (in Shares) Mezzanine equity, shares issued (in Shares) Mezzanine equity, shares outstanding (in Shares) STOCKHOLDERS’ EQUITY (DEFICIT) Preferred stock, value Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized (in Shares) Preferred stock, shares authorized Preferred stock, shares issued (in Shares) Preferred stock, shares outstanding (in Shares) Quantity Issued and Outstanding Preferred stock outstanding Common stock, $0.001 par value, 1,000,000,000 and 100,000,000 shares authorized, 38,631 and 15,297 shares issued and 38,630 and 15,296 shares outstanding, respectively Aggregate offering price (in Dollars) Common stock, par value (in Dollars per share) Common stock, shares authorized (in Shares) Common stock, shares issued (in Shares) Common stock share issued Common stock, shares outstanding (in Shares) Treasury stock (in Shares) Additional paid-in capital Accumulated deficit Accumulated other comprehensive income NON-CONTROLLING INTEREST REVENUE Sales Cost of goods sold OPERATING EXPENSES General and administrative expenses $0 and $0 in stock-based compensation, respectively Stock-based compensation Research and development $0 and $10,000 in stock-based compensation, respectively Sales and marketing $0 and $0 in stock-based compensation, respectively Sales and marketing costs OTHER INCOME (EXPENSE) Interest income NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST Net loss attributable to non-controlling interest Net loss per share, basic (in Dollars per share) Net loss per share, diluted (in Dollars per share) Weighted average number of shares outstanding during the period, basic (in Shares) Weighted average number of shares outstanding during the period, diluted (in Shares) COMPREHENSIVE LOSS: Other Comprehensive Income: Issuance of shares for registered direct offering, net of issuance costs Issuance of shares for registered direct offering, net of issuance costs (in Shares) Number, Issued due to resets Number of shares sold New issues (in Shares) Reclass of derivative liability from warrants Fair value of derivative liability of warrants Redemption of preferred stock Redemption of preferred stock (in Shares) Reclass of preferred stock to Mandatorily Redeemable Preferred Stock Reclass of preferred stock to Mandatorily Redeemable Preferred Stock (in Shares) Ignite Acquisition Ignite Acquisition (in Shares) Shares acquired Rounding from reverse stock split Change in Evofem note receivable Derivative liability from conversion feature on preferred stock Issuance of shares under ELOC, net of issuance costs Issuance of shares under ELOC, net of issuance costs (in Shares) CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to reconcile net loss to net cash used in operating activities Stock-based compensation from asset purchase Depreciation expense Amortization of intangible assets Amortization expenses Amortization of debt discount - note payable Amortization of debt discount Amortization of debt discount Change in fair value of derivative liability Change in fair value of derivative liabilities Fair value of derivative liability Fair value of warrant Change in fair value of Evofem warrants Change in fair value of Evofem warrants Change in fair value of Evofem Warrants Change in the fair value of the Evofem warrants Impairment of fixed assets Impairment Changes in operating assets and liabilities: Accounts payable and accrued expenses CASH FLOWS FROM INVESTING ACTIVITIES: CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from notes and convertible notes payable, net of offering costs Repayments of note payable, related party Common stock, preferred stock, and warrants issued for cash, net of issuance costs Cash from subscription receivable Supplemental cash flow information: Cash paid for income taxes Cash paid for interest NONCASH INVESTING AND FINANCING ACTIVITIES: Derivative liability from conversion feature on warrants Warrant reprices reclassed to derivative liability (in Dollars) Derivative liability from conversion feature on preferred stock ELOC payable Series C-1 redemption payable ELOC commitment fee stock payable Reclassification of series A-1 preferred shares to liabilities Conversion of Series A-1 to common stock Treasury stock, 1 and 1 shares, respectively Interest expense Income tax provision Provisions for income taxes